Clearside Biomedical, Inc. 8-K Filing
Ticker: CLSDQ · Form: 8-K · Filed: Dec 29, 2025 · CIK: 1539029
| Field | Detail |
|---|---|
| Company | Clearside Biomedical, Inc. (CLSDQ) |
| Form Type | 8-K |
| Filed Date | Dec 29, 2025 |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Clearside Biomedical, Inc. (ticker: CLSDQ) to the SEC on Dec 29, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ich registered Common Stock, par value $0.001 per share CLSD The Nasdaq Stock Mar).
How long is this filing?
Clearside Biomedical, Inc.'s 8-K filing is 5 pages with approximately 1,521 words. Estimated reading time is 6 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 1,521 words · 6 min read · ~5 pages · Grade level 14.9 · Accepted 2025-12-29 06:14:20
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share CLSD The Nasdaq Stock Mar
Filing Documents
- d63805d8k.htm (8-K) — 34KB
- d63805dex991.htm (EX-99.1) — 86KB
- g63805dsp006.jpg (GRAPHIC) — 126KB
- g63805dsp007.jpg (GRAPHIC) — 162KB
- g63805dsp008.jpg (GRAPHIC) — 113KB
- g63805dsp009.jpg (GRAPHIC) — 94KB
- g63805dsp010.jpg (GRAPHIC) — 104KB
- g63805dsp011.jpg (GRAPHIC) — 92KB
- g63805dsp012.jpg (GRAPHIC) — 93KB
- g63805dsp013.jpg (GRAPHIC) — 148KB
- g63805dsp014.jpg (GRAPHIC) — 182KB
- g63805dsp015.jpg (GRAPHIC) — 337KB
- g63805dsp016.jpg (GRAPHIC) — 333KB
- g63805dsp017.jpg (GRAPHIC) — 185KB
- 0001193125-25-332152.txt ( ) — 2957KB
- clsd-20251219.xsd (EX-101.SCH) — 3KB
- clsd-20251219_lab.xml (EX-101.LAB) — 18KB
- clsd-20251219_pre.xml (EX-101.PRE) — 11KB
- d63805d8k_htm.xml (XML) — 4KB
Forward-Looking Statements Disclaimer
Forward-Looking Statements Disclaimer This Current Report contains certain forward-looking statements. These forward-looking statements are subject to considerable risks and uncertainties, and these forward-looking statements may be identified by words such as "believe", "expect", "may", "plan", "potential", "will", "estimates", "intends" and similar expressions, and are based on the Company's current beliefs and expectations, including without limitation, statements regarding the Company's current expectations and intentions with respect to the Bidding Procedures and a purchase agreement with respect to the proposed transaction as set forth in the Stalking Horse Bid. It is very difficult to predict the effect of known factors, and the Company cannot anticipate all factors that could affect actual results that may be important to an investor. All forward-looking information should be evaluated in the context of these risks, uncertainties and other factors, including: risks attendant to the bankruptcy process, including the Company's ability to obtain court approval from the Court with respect to motions or other requests made to the Court throughout the course of the Case; the Company's ability to negotiate and confirm a sale of its assets under Section 363 of the Bankruptcy Code; the effects of the Case on the Company's liquidity (including the availability of operating capital during the pendency of the Case), results of operations, business prospects and costs, including increased legal and other professional costs necessary to facilitate the Case; the effects of the Case on the interests of various constituents and financial stakeholders; the length of time that the Company will operate under Chapter 11 protection and the continued availability of operating capital during the pendency of the Case; objections to the Company's restructuring process or other pleadings filed that could protract the Case; risks associated with third-party motions in the Case; Cou
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 29, 2025 CLEARSIDE BIOMEDICAL, INC. By: /s/ Charles A. Deignan Name: Charles A. Deignan Title: Chief Financial Officer